We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Which Shunt Best for Repairing Congenital Heart Defects?

By HospiMedica International staff writers
Posted on 30 Nov 2009
A new study compares two surgical strategies for repairing the severely underdeveloped heart, the most common severe congenital heart defect.

Infants born with a critically underdeveloped left side of their hearts require three surgeries to correct the problem. More...
The first stage involves the Norwood Procedure, which is used to form a connection that delivers blood from the heart to the pulmonary arteries, to pick up oxygen. This can be done by two procedures; the traditional version uses a modified Blalock-Taussig shunt (MBTS), which connects the aorta the pulmonary artery; the modified procedure uses a right ventricle to pulmonary artery (RV-to-PA) shunt to connect the functioning right ventricle to the pulmonary artery.

Researchers at the University of Michigan Medical School (Ann Arbor, USA) and other members of the international Pediatric Heart Network conducted a 15-center trial involving 555 infants (61% male) who were randomized to receive either the RV-to-PA shunt or MBTS procedure. The initial results of the study found that at 12 months, significantly more babies survived without requiring a heart transplant with the RV-to-PA shunt (74%) compared to the MBTS (64%). The RV-to-PA shunt, on the other hand, had more complications, necessitating 240 interventions (87.6 for every 100 babies), such as adjusting the shunt or using stents to keep it open; far fewer cardiovascular interventions were needed--183, or 66.5 for every 100 babies--in the MBTS group. However, at an average of two years, the transplant-free survival advantage of RV-to-PA (68%) over MBTS (62%) had diminished and it was no longer significant. The study was presented at the American Heart Association (AHA) scientific sessions, held during November 2009 in Chicago (IL, USA).

"Early results seem to favor the RV-PA shunt, but by two years there is no longer any survival advantage. It is still unknown which will turn out to be better over the long term,” said lead author Richard Ohye, M.D., an associate professor of surgery at the U-Mich. "Ongoing surveillance as these children grow and undergo the final surgical procedure will be very important to determine the proper roles of the shunts.”

Both shunt procedures have theoretical advantages and disadvantages. The downside of the MBTS is that it takes blood away from the arteries feeding the heart muscle. The RV-to-PA shunt does not do this, but requires an incision into the single working ventricle, creating scarring that might interfere with later function.

Related Links:

Michigan Medical School
Pediatric Heart Network



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.